Pharma, Pharmaceutics and Biotechnology Conference

Pharmacological testing is one of the basic steps in new drug development aimed at examining the safety, efficacy, and pharmacological characteristics of new therapeutic drugs before hitting the market.

In this session, we will take a detailed review of the various testing methods applied throughout the drug development pipeline-from preclinical checks through clinical trials-of special emphasis on how state-of-the-art technologies are enhancing both accuracy and efficiency.

Actually, it begins in the preclinical phase with pharmacological testing, through which possible candidates as drugs are strictly evaluated by the use of in vitro and in vivo methods. In vitro testing refers to experiments performed in a very controlled environment inside the laboratory.

The compound could be tested for its biological activity in cell cultures or by biochemical assays. In contrast, in vivo testing typically is synonymous with testing the compound using living organisms, mainly animal models.

The following is how such methods complement each other and provide some very important data relating to the drug's mechanism of action, toxicity, and pharmacokinetics. Advances in technology are transforming pharmacological testing of drugs at a rapid pace.

High-throughput screening, computational modeling, and organ-on-a-chip technologies are changing the face of drug testing. Such technologies allow researchers to understand drug behavior and interactions much more accurately than was previously possible and avoid animal testing as much as possible.

It will be interesting to learn how such innovations can accelerate drug discovery without getting new therapies into the clinic without preclinical data that raise concerns about safety and efficacy.

This is also considered a transitional phase in drug development. Clinical pharmacological testing of drugs contains the effect of the drug on human volunteers or patients at various stages.

In this session, early-phase drug development studies such as Phase I on safety and dosage, and later stages like Phase II and III on efficacy, side effects, and optimum use of drugs in therapeutic practice would be discussed. Pharmacodynamics (how the drug acts on the body) and pharmacokinetics (the way the body treats the drug) will be acquired by the audience, which are 'bottom line' points that determine whether clinical trials are successful or not.

Since drugs must meet strict standards in safety and efficacy as a precondition for approval, regulatory matters are regarded as the heart of pharmacological testing.

The discussion shall include the role of regulatory agencies in pharmaceutical testing in ensuring that the highest level of standards is attained and maintained during the drug development process.

At the end of this session, one would be equipped to understand how pharmacological testing is to be conducted, the latest innovations in testing methods, and the important role that these tests play in bringing safe effective drugs onto the market.

This session would consist of a number of presentations and discussions to deliver invaluable insights concerning the shifting landscape of pharmacological testing and its subsequent impact on healthcare-from research to drug developer to regulatory affairs.

Therefore, with such a history of experience, attendees will thus leave with practical knowledge on how to carry out effective testing strategies and deploy advanced technologies in the improvement of the efficiency and accuracy of drug development.